ERBB2 and breast cancer: Additionally, preliminary safety results from the ongoing phase IIIb PERUSE study (NCT01572038) have shown that both paclitaxel and nab-paclitaxel appear to be feasible and tolerable chemotherapy partners for trastuzumab and pertuzumab for first-line HER2-positive advanced breast cancer, with no unexpected safety signals observed [28].